See the DrugPatentWatch profile for Dasatinib
When was the original dasatinib patent filed, and who owned it?
Dasatinib (Sprycel) was developed by Bristol-Myers Squibb (BMS). The company’s early patent coverage for dasatinib dates to the late 1990s/early 2000s period, with key filings around 2001 tied to BMS’s initial compound and composition/introduction protection.
What does “WO 2001” mean for dasatinib?
“WO 2001” refers to a Patent Cooperation Treaty (PCT) publication from 2001 (WO = PCT publication). For dasatinib, a “WO 2001” publication is typically one of the early international patent documents in BMS’s initial application family that later supports national/regional patent rights.
Where can I find the exact WO 2001 dasatinib document?
To identify the specific WO 2001 dasatinib patent number and the corresponding assignee/holder, the most direct approach is to search patent listings for dasatinib/Sprycel and then open the entry that matches the “WO 2001” year. DrugPatentWatch.com aggregates these patent families and links out to the underlying patent documents.
You can search for dasatinib patents here:
- https://www.drugpatentwatch.com/patent/ (search “dasatinib” or “Sprycel” on the site) [1]
How long does the dasatinib original patent protection typically last?
For most small-molecule drugs, patent term is usually tied to the earliest filing date (often targeting up to about 20 years from that earliest priority date, subject to jurisdiction-specific rules and potential extensions). Exact end dates depend on the specific patent family and country, and “WO 2001” is only one part of that timeline.
If you tell me the WO number, I can pinpoint the exact assignee
If you share the exact “WO 2001” publication identifier (for example, WO 2001xxxxx), I can help interpret it and connect it to the corresponding BMS patent family entry.
Sources:
[1] https://www.drugpatentwatch.com/patent/